# Arylmethylamino steroid compound 1o interferes with Plasmodium falciparum’s hemoglobin metabolism

**Authors:** Eric Springer, Kim C. Heimsch, Niklas Sidiropoulos, Jacomina Krijnse Locker, Jude M. Przyborski

PMC · DOI: 10.1128/aac.00332-25 · Antimicrobial Agents and Chemotherapy · 2025-06-23

## TL;DR

A new compound, 1o, shows promise against malaria by interfering with the parasite's hemoglobin metabolism and affecting early stages of its life cycle.

## Contribution

The study reveals a novel mode of action for 1o by linking its effects to hemoglobin metabolism and early parasite development.

## Key findings

- 1o increases cytosolic ATP levels and slightly lowers pH in Plasmodium falciparum.
- 1o prevents chloroquine-mediated heme and hemoglobin accumulation and preserves food vacuole integrity.
- 1o blocks development of ring and early trophozoite stages but not late trophozoite stages.

## Abstract

The anti-parasitic compound arylmethylamino steroid 1o (1o) is a promising drug candidate with low nanomolar activity against the malaria parasite Plasmodium falciparum, but with a so far unknown mode of action. To address this, we applied previously developed live-cell ATP and pH assays to measure effects upon exposure of parasites to 1o. Furthermore, we analyzed the parasites’ heme species distribution, the ultrastructural morphology, food vacuole (FV) appearance, and lifecycle development of different parasite stages. We found that 1o increases cytosolic [ATP] level and causes a slight drop in pH, similar to the effects of arylamino alcohols such as mefloquine. The compound also prevents chloroquine (CQ)-mediated proteolysis and limits cytosol acidification within the range of its EC50. Additionally, 1o prevents CQ-mediated heme and hemoglobin accumulation, and preserves ultrastructural FV integrity. Furthermore, we can demonstrate that 1o blocks the development of ring and early trophozoite stages, while late trophozoite stages were unaffected. These findings suggest that the mechanism underlying the killing activity of 1o may be the interference of a pathway within or upstream of hemoglobin digestion, particularly during the highly metabolically active earlier parasite stages. Our data open a new perspective on the compound’s mode of action, information critically needed for target identification and further drug development.

## Linked entities

- **Chemicals:** 1o (PubChem CID 155488070), chloroquine (PubChem CID 2719), mefloquine (PubChem CID 4046)
- **Diseases:** malaria (MONDO:0005136)
- **Species:** Plasmodium falciparum (taxon 5833)

## Full-text entities

- **Diseases:** malaria (MESH:D008288)
- **Chemicals:** CQ (MESH:D002738), arylmethylamino steroid 1o (MESH:C000712271), mefloquine (MESH:D015767), ATP (MESH:D000255), heme (MESH:D006418), 1o (-)
- **Species:** Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12327009/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12327009/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12327009/full.md

---
Source: https://tomesphere.com/paper/PMC12327009